Allergen Immunotherapy in the Age of Coronavirus: A Review of Practice Considerations and Evidence to Deliver Uninterrupted Care – September 23

Wednesday, September 23, 2020
9:00 PM – 11:00 PM EST



As with many other components of patient care and medical delivery, the coronavirus pandemic has caused unprecedented disruptions and created barriers to the administration of allergen immunotherapy (AIT). The disruption of AIT may place patients at increased risk for an allergic reaction and have a deleterious effect on patient quality of life. At the same time, many of the patients who depend on AIT may also be vulnerable to the most devastating effects of COVID-19. Given these factors, clinicians may be uncertain as to how best reengage patients for AIT, ensure care is delivered appropriately and effectively, and ensure patient, staff, and provider safety.  This educational activity will equip clinicians with strategies to manage AIT during the COVID-19 pandemic. In addition, recent safety and efficacy data from clinical trials and the impact of COVID-19 on AIT research will be reviewed in the context of patient care to inform AIT best practices in the face of current challenges.


This educational initiative has been designed for allergists, otolaryngologists, otolaryngic allergists, nurse practitioners, and physician assistants involved in the management of patients receiving allergen immunotherapy.


Upon completion of this educational activity, participants should be able to:

  • Integrate current COVID-19 protocols, AIT management strategies, and patient communication approaches to ensure optimal outcomes for patients on AIT
  • Review recent safety and efficacy outcomes from clinical trials involving AIT
  • Describe the impact of COVID-19 on research and guidance from the FDA to address the evolving demands of clinical trials during the pandemic


A detailed disclosure for all persons in control of content, including faculty presenters, will be provided at the live event.


Physician Continuing Education

Accreditation Statement
Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education designates each live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or


Integrity Continuing Education requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This CME activity is provided by Integrity Continuing Education.


This activity is supported by an educational grant from ALK-Abello, Inc.



2-hour CME Presentation followed by an optional (non-certified) 30 minute session on the impact of COVID-19 on research.

On the day of the event click to view this event.